Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051809 | 0.87 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL2596731 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL9051812 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL9051815 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL36924 | 0.77 | ALDH1A1 (0.60) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL307762 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL29981558 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL1342303 | 0.75 | ALDH1A1 (0.63) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL15899084 | 0.74 | SMN1; SMN2 (0.53) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 | |
| SCHEMBL23683541 | 0.74 | ALDH1A1 (0.62) | ALDH1A1TDP1L3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | U.S. DEPARTMENT OF ENERGY | 2019-05-23 | — | — | US | disclosed |
| EP-2568807-B1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | UNIV MISSISSIPPI STATE (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9227937-B2 | Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning | MISSISSIPPI STATE UNIVERSITY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | MISSISSIPPI STATE UNIVERSITY | 2013-07-04 | — | — | US | disclosed |
| EP-2568807-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | Mississipi State University (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011142826-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | MISSISSIPI STATE UNIVERSITY (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | ACHE, BCHE, CHAT | ALDH1A1 1411/4885TDP1 99/4885L3MBTL1 1234/4885 |
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | PNPO, PLPBP, PDXK | ALDH1A1 2536/4885TDP1 589/4885L3MBTL1 996/4885 |
| US-11186548-B2 | Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them | ACHE, BCHE, CHAT | ALDH1A1 1411/4885TDP1 99/4885L3MBTL1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.